This company listing is no longer active
HEXO Past Earnings Performance
Past criteria checks 0/6
HEXO's earnings have been declining at an average annual rate of -42.2%, while the Pharmaceuticals industry saw earnings growing at 19.4% annually. Revenues have been growing at an average rate of 39.8% per year.
Key information
-42.2%
Earnings growth rate
-4.5%
EPS growth rate
| Pharmaceuticals Industry Growth | 7.3% |
| Revenue growth rate | 39.8% |
| Return on equity | -191.4% |
| Net Margin | -220.1% |
| Last Earnings Update | 30 Apr 2023 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How HEXO makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Apr 23 | 124 | -273 | 61 | 1 |
| 31 Jan 23 | 148 | -301 | 86 | 1 |
| 31 Oct 22 | 177 | -1,013 | 105 | 3 |
| 31 Jul 22 | 191 | -1,074 | 122 | 3 |
| 30 Apr 22 | 187 | -1,042 | 128 | 4 |
| 31 Jan 22 | 164 | -918 | 109 | 4 |
| 31 Oct 21 | 144 | -228 | 96 | 4 |
| 31 Jul 21 | 124 | -115 | 80 | 4 |
| 30 Apr 21 | 112 | -214 | 75 | 4 |
| 31 Jan 21 | 112 | -213 | 75 | 4 |
| 31 Oct 20 | 96 | -491 | 78 | 4 |
| 31 Jul 20 | 81 | -546 | 91 | 5 |
| 30 Apr 20 | 69 | -423 | 115 | 7 |
| 31 Jan 20 | 60 | -411 | 119 | 6 |
| 31 Oct 19 | 56 | -117 | 114 | 5 |
| 31 Jul 19 | 48 | -70 | 105 | 3 |
| 30 Apr 19 | 34 | -35 | 73 | 0 |
| 31 Jan 19 | 22 | -30 | 54 | 0 |
| 31 Oct 18 | 9 | -34 | 41 | 0 |
| 31 Jul 18 | 5 | -23 | 23 | 0 |
| 30 Apr 18 | 4 | -12 | 15 | 0 |
| 31 Jan 18 | 4 | -22 | 12 | 0 |
| 31 Oct 17 | 4 | -14 | 9 | 0 |
| 31 Jul 17 | 4 | -12 | 7 | 0 |
| 30 Apr 17 | 4 | -15 | 7 | 0 |
| 31 Jan 17 | 4 | -3 | 5 | 0 |
| 31 Oct 16 | 3 | -3 | 4 | 0 |
| 31 Jul 16 | 2 | -3 | 4 | 0 |
| 31 Jul 15 | 0 | -3 | 2 | 0 |
Quality Earnings: 74H is currently unprofitable.
Growing Profit Margin: 74H is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 74H is unprofitable, and losses have increased over the past 5 years at a rate of 42.2% per year.
Accelerating Growth: Unable to compare 74H's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 74H is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (9.4%).
Return on Equity
High ROE: 74H has a negative Return on Equity (-191.4%), as it is currently unprofitable.